https://www.pharmaceutical-technology.com/data-insights/cedazuridine-decitabine-otsuka-pharmaceutical-relapsed-acute-myeloid-leukemia-likelihood-of-approval/
(Cedazuridine + decitabine) is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Relapsed Acute Myeloid Leukemia.
acute myeloid leukemiaotsuka pharmaceuticalcedazuridinedecitabinerelapsed
https://www.hmpgloballearningnetwork.com/site/onc/news/decitabine-plus-cedazuridine-maintenance-therapy-shows-promising-survival-outcomes
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk...
maintenance therapydecitabinepluscedazuridineshows